Oxaliplatin and capecitabine (CAPOX) is active and feasible for irinotecan refractory metastatic colorectal carcinoma (MCRC)

被引：0

作者：

Munoz, Alberto ^{[1
]}

Viteri, Ainboa ^{[1
]}

Rubio, Itziar ^{[1
]}

Alvarez, Aitor ^{[1
]}

Mane, Joan M. ^{[1
]}

Pardo, Marta ^{[1
]}

Fernandez, Ricardo ^{[1
]}

Lopez-Argumedo, Gonzalo ^{[1
]}

Barcelo, Ramon ^{[1
]}

Lopez-Vivanco, Guillermo ^{[1
]}

机构：

[1] Hosp Cruces, Baracaldo, Spain

来源：

ANNALS OF ONCOLOGY | 2004年 / 15卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：92 / 92

页数：1

共 50 条

[21] A phase II study of capecitabine, oxaliplatin and irinotecan (XELOXIRI) as salvage therapy in patients with refractory metastatic colorectal cancer.
Kwok, Gin Wai
Leung, Roland Ching-Yu
Chiu, Joanne
Tang, Vikki
Yau, Thomas Cheung
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[22] Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
Lenz, Heinz-Josef
Van Cutsem, Eric
Khambata-Ford, Shirin
Mayer, Robert J.
Gold, Philip
Stella, Philip
Mirtsching, Barry
Cohn, Allen L.
Pippas, Andrew W.
Azarnia, Nozar
Tsuchihashi, Zenta
Mauro, David J.
Rowinsky, Eric K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4914 - 4921
[23] A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
Fornaro, Lorenzo
Masi, G.
Bursi, S.
Loupakis, F.
Vasile, E.
Antonuzzo, A.
Chiara, S.
Pfanner, E.
Di Paolo, A.
Bocci, G.
Del Tacca, M.
Falcone, A.
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (05) : 965 - 969
[24] A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
Lorenzo Fornaro
G. Masi
S. Bursi
F. Loupakis
E. Vasile
A. Antonuzzo
S. Chiara
E. Pfanner
A. Di Paolo
G. Bocci
M. Del Tacca
A. Falcone
[J]. Cancer Chemotherapy and Pharmacology, 2009, 63 : 965 - 969
[25] Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)
Cassinello, J.
Alvarez, J. V.
Garcia-Lopez, M. J.
Pujol, E.
Colmenarejo, A.
De Segovia, F.
Marcos, F.
Filipovich, E.
[J]. EJC SUPPLEMENTS, 2005, 3 (02): : 199 - 200
[26] Phase II study of capecitabine plus oxaliplatin (XELOX) followed by capecitabine plus irinotecan (XELIRI) in a sequential schedule in first-line metastatic colorectal cancer (MCRC)
Cassinello, Javier
Alvarez, Jose V.
Garcia Lopez, Maria J.
Pujol, Eduardo
Colmenarejo, Antonio
De Segovia, Fernando
Marcos, Fernando
Filipovich, Elena
Arcediano, Alberto
Garcia Castro, Ines
[J]. ANNALS OF ONCOLOGY, 2006, 17 : 116 - 117
[27] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST - LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
Adda, B.
Farida, S.
[J]. ANNALS OF ONCOLOGY, 2009, 20 : 73 - 73
[28] First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the GONO group
Burs, S.
Masi, G.
Loupakis, F.
Antonuzzo, A.
Tognarini, L.
Sonaglio, C.
Chiara, S.
Pfanner, E.
Brunetti, I
Petrini, I
Baldi, G.
Barletta, M.
Allegrini, G.
Ricci, S.
Falcone, A.
[J]. ANNALS OF ONCOLOGY, 2007, 18 : VII27 - VII27
[29] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST -LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
Bounedjar, A.
Smail, F.
[J]. ANNALS OF ONCOLOGY, 2010, 21 : 67 - 68
[30] Compliance and toxicity in metastatic colorectal carcinoma patients treated with capecitabine versus 5-FU associated with oxaliplatin or irinotecan
Raimondi, C.
Longo, F.
Tomao, S.
Ricciardi, S.
Rosati, S.
Messina, C. G. M.
Cerbone, L.
Spalletta, B.
Russillo, M.
Di Seri, M.
[J]. ANNALS OF ONCOLOGY, 2006, 17 : XI43 - XI43

← 1 2 3 4 5 →